• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Names New External Affairs Leader

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak.

    "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what opportunities we can unlock as he takes the helm of our External Affairs function globally."

    Since joining PMI in 2003, Mr. Harpantidis has held several positions, including setting the commercialization strategy for smoke-free products in Lausanne, Switzerland, and serving as Chairman and Managing Director of Papastratos in Greece. Most recently, he served as Area Vice President of the South East Europe Area. Throughout his career at PMI, he has strongly contributed to growing the company's smoke-free consumer base, expanding its brand portfolio, and advocating for regulations consistent with PMI's smoke-free ambitions. Prior to joining the company, he worked at Coca-Cola Hellenic. Mr. Harpantidis holds a degree in physics from the Aristotle University of Thessaloniki, Greece, as well as master's degrees in economics and business administration from Kent University in the United Kingdom.

    "Leading our dynamic External Affairs function globally is an enormous honor," said Christos Harpantidis. "I look forward to building on the remarkable progress already achieved by the team, which is resulting in science-based tobacco harm reduction policies being endorsed by more countries. I am incredibly proud of the work we are doing to transform our company and of the way civil society is coming together to support us. Still, more must be done. To realize our world-changing vision, we must continue to engage in transparent dialogue, build trust in the evidence, and work closely with policymakers and public health stakeholders to accelerate change."

    This appointment follows the decision of Grégoire Verdeaux to leave PMI at the end of April to pursue other professional opportunities. During his tenure, Mr. Verdeaux expanded the company's global tobacco harm reduction strategy and, with the team, built compelling policy positions and advocated for regulations consistent with our smoke-free ambitions.

    "Thanks, in large part, to Grégoire's efforts, tobacco harm reduction policies are now endorsed by a growing number of countries," said Mr. Olczak. "Under Christos' leadership, I believe that the External Affairs function will ensure that this positive momentum is maintained and further amplified."

    Philip Morris International: Delivering a Smoke-Free Future

    Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies' IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI's IQOS Platform 1 devices and consumables and Swedish Match's General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37 percent of PMI's total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240326602014/en/

    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    10/21/25 7:03:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    9/19/25 7:02:44 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    9/2/25 9:04:47 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

    3 - Philip Morris International Inc. (0001413329) (Issuer)

    6/9/25 3:34:30 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:43 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International upgraded by UBS with a new price target

    UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

    4/25/25 8:25:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

    Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth an

    10/21/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International to Host Webcast of 2025 Third-Quarter and First Nine-Months Results

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast on Tuesday, October 21, 2025, at 9:00 a.m. ET, to discuss its 2025 third-quarter and first nine-months results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast can be accessed here. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The webcast recording and the slides and script

    10/14/25 8:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product

    A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes "Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.'" Experts from Philip Morris International Inc. (NYSE:PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to

    10/8/25 10:51:00 AM ET
    $PM
    $PMI
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical/Dental Instruments

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    3/4/24 6:48:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

    Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth an

    10/21/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) has increased the company's regular quarterly dividend by 8.9% to an annualized rate of $5.88 per share. The new quarterly dividend of $1.47 per share, up from $1.35 per share, is payable on October 20, 2025, to shareholders of record as of October 3, 2025. The ex-dividend date is October 3, 2025. PMI has increased its annual dividend every year since becoming a public company in 2008, representing a total increase of 219.6%, or a compound annual growth rate of 7.1%. For additional dividend information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Ph

    9/19/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

    7/22/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care